List of select clinical trials for treatment of patients with RS
| Reference . | Treatment regimen . | Accrual period . | n . | Median age, years (range) . | Response rate (%) . | Allogeneic SCT (%) . | Grade 3/4 toxicity (%) . | TRM (%) . | Median survival . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CR . | ORR . | Neutropenia . | Thrombopenia . | Infection . | ||||||||
| Anthracycline-containing regimens | ||||||||||||
| 68 | R-CHOP | NR | 15 | 69 (NR) | 7 | 67 | NR | 55 | 65 | 28 | 3 | 27 months |
| 70 | HyperCVXD | NR | 29 | 61 (36-75) | 38 | 41 | NR | 100 | 79 | 39 | 14 | 10 months |
| 71 | Rituximab and GM-CSF with alternating hyperCVXD and MTX/cytarabine | 1999-2001 | 30 | 59 (27-79) | 27 | 43 | NR | 100 | 40 | 59 | 18 | 8 months |
| Platinum-containing regimens | ||||||||||||
| 72 | OFAR1 | 2004-2006 | 20 | 59 (34-77) | 10 | 50 | 15 | 84 | 94 | 12 | 7 | 8 months |
| 69 | OFAR2 | 2007-2010 | 35 | 63 (40-81) | 6 | 43 | 20 | 89 | 77 | 20 | NR | 6.6 months |
| Fludarabine-containing regimens | ||||||||||||
| 73 | PFA or CFA | 1992-1996 | 12 | 59 (49-74) | 18 | 45 | NR | NR | NR | NR | NR | 17 months |
| 74 | FACPGM | 1997-2001 | 15 | 62 (42-74) | 5 | 5 | 0 | 90 | 83 | 55 | 20 | 2.2 months |
| Radioimmunotherapy | ||||||||||||
| 75 | 90Y ibritumomab tiuxetan | 2000-2002 | 7 | 56 (44-70) | 0 | 0 | 0 | 29 | 71 | 13 | NR | NR |
| Reference . | Treatment regimen . | Accrual period . | n . | Median age, years (range) . | Response rate (%) . | Allogeneic SCT (%) . | Grade 3/4 toxicity (%) . | TRM (%) . | Median survival . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CR . | ORR . | Neutropenia . | Thrombopenia . | Infection . | ||||||||
| Anthracycline-containing regimens | ||||||||||||
| 68 | R-CHOP | NR | 15 | 69 (NR) | 7 | 67 | NR | 55 | 65 | 28 | 3 | 27 months |
| 70 | HyperCVXD | NR | 29 | 61 (36-75) | 38 | 41 | NR | 100 | 79 | 39 | 14 | 10 months |
| 71 | Rituximab and GM-CSF with alternating hyperCVXD and MTX/cytarabine | 1999-2001 | 30 | 59 (27-79) | 27 | 43 | NR | 100 | 40 | 59 | 18 | 8 months |
| Platinum-containing regimens | ||||||||||||
| 72 | OFAR1 | 2004-2006 | 20 | 59 (34-77) | 10 | 50 | 15 | 84 | 94 | 12 | 7 | 8 months |
| 69 | OFAR2 | 2007-2010 | 35 | 63 (40-81) | 6 | 43 | 20 | 89 | 77 | 20 | NR | 6.6 months |
| Fludarabine-containing regimens | ||||||||||||
| 73 | PFA or CFA | 1992-1996 | 12 | 59 (49-74) | 18 | 45 | NR | NR | NR | NR | NR | 17 months |
| 74 | FACPGM | 1997-2001 | 15 | 62 (42-74) | 5 | 5 | 0 | 90 | 83 | 55 | 20 | 2.2 months |
| Radioimmunotherapy | ||||||||||||
| 75 | 90Y ibritumomab tiuxetan | 2000-2002 | 7 | 56 (44-70) | 0 | 0 | 0 | 29 | 71 | 13 | NR | NR |
FACPGM, fludarabine, cytarabine, cyclophosphamide, cisplatin, granulocyte-monocyte colony stimulating factor; GM-CSF, granulocyte-monocyte colony stimulating factor; MTX, methotrexate; NR, not reported; TRM, treatment-related mortality.